ASH 2021 | Efficacy of PARP inhibitors in the treatment of AML
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses the use of poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of acute myeloid leukemia (AML). Dr Wang first explains some background information on the promising activity of PARP inhibitors, and then discusses the potential use of these inhibitors to enhance the effectiveness of conventional chemotherapies. Dr Wang then draws focus on some results which demonstrated that the PARP inhibitor talazoparib is able to enhance the effect of venetoclax, and the promising applications that these findings may have in future triplet combinations for the treatment of AML. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
